Advertisement

Topics

EU Confirms Sirukumab Filing Withdrawal, J&J Moves On

04:03 EST 13 Nov 2017 | SCRIP

Janssen-Cilag has withdrawn the EU marketing application for the IL-6 inhibitor sirukumab, with the CHMP saying the long-term safety of...

      

Related Stories

 

Original Article: EU Confirms Sirukumab Filing Withdrawal, J&J Moves On

NEXT ARTICLE

More From BioPortfolio on "EU Confirms Sirukumab Filing Withdrawal, J&J Moves On"

Advertisement
Quick Search
Advertisement
Advertisement